PatientView | Austria insights from Patient Groups: A seat at the pricing table

Survey insights

39 patient group respondents from Austria, informed us how they interact and engage with drug regulators to ensure equitable or more affordable access to medicines.

Regularly or sometimes 23%
Other responses 77%

23% of respondents from Austria ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators.

Total number of patients reached = ~207K

Patients reached by each patient group (5 respondents).

Patient group voices

interactions

Exchanges relating to HTA [Health Technology Assessment] and the reimbursement authority.

National gastrointestinal patient group

interactions

HTA [Health Technology Assessment] — regulatory advisory capacity.

International respiratory patient group

actions & advocacy

Participation in political working groups and committees, e.g. those focused on rare diseases.

National children's-health patient group

actions & advocacy

In cases of rejection or supply shortages.

National diabetes patient group

Patient group goals

The percentages below highlight how the 9 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.

interactions

How patient groups interact with drug regulators

Find out what the goals mean

3 mentions

actions & advocacy

How patient groups get access to medicines

Find out what the goals mean

2 mentions

1 mention

English text	Therapy area	Category	Patients reached	Geo reach	Regulatory engagement	Respondent
HTA [Health Technology Assessment] Assessments — Regulatory advisory capacity.	Respiratory > Asthma and allergy	Regulatory partnership > Participate in Health Technology Assessment (HTA) and reimbursement reviews	Over 100,000	International	Sometimes	119038257640
Exchanges relating to HTA [Health Technology Assessment] and the reimbursement authority.	Gastrointestinal > IBD	Regulatory partnership > Participate in Health Technology Assessment (HTA) and reimbursement reviews	5,000	National	Sometimes	119078646517
HTA [Health Technology Assessment] Assessments — Regulatory advisory capacity.	Respiratory > Asthma and allergy	Regulatory partnership > Attend/facilitate meetings with policymakers/regulators	Over 100,000	International	Sometimes	119038257640
Participation in political working groups and committees, e.g. those focused on rare diseases.	Children's health > Children: chronic diseases	Impacting policy and legislation > Influence healthcare policy and legislation	1,000	National	Sometimes	119054988772
Participation in political working groups and committees, e.g. those focused on rare diseases.	Children's health > Children: chronic diseases	Impacting policy and legislation > Mobilise parliamentarians and political leaders	1,000	National	Sometimes	119054988772
Treatment availability and/or cost.	Neurological > Multiple sclerosis	Pricing and affordability advocacy > Advocate for fair medicine pricing	1,000	Regional	Rarely	119060630623
In cases of rejection or supply shortages [in Austria].	Endocrine > Diabetes (both types 1 and 2)	Pricing and affordability advocacy > Tracking and monitoring drug pricing/drug shortages	100,000	National	Sometimes	119078380814
Treatment availability and/or cost.	Neurological > Multiple sclerosis	Improving access pathways > Facilitate equitable access to medicines/healthcare	1,000	Regional	Rarely	119060630623

GET THE REPORT

Access the full findings

Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.

Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com

Download sample reports

Download country report

Download therapy report